SenesTech, Inc. (SNES) Bundle
Understanding SenesTech, Inc. (SNES) Revenue Streams
Revenue Analysis
SenesTech, Inc. reported revenue of $1.98 million for the fiscal year ending December 31, 2023, compared to $2.37 million in 2022.
Revenue Source | 2023 Revenue ($) | Percentage of Total Revenue |
---|---|---|
Product Sales | 1,450,000 | 73.2% |
Service Revenue | 530,000 | 26.8% |
Revenue breakdown by geographic region:
Region | 2023 Revenue ($) | Percentage of Total Revenue |
---|---|---|
North America | 1,250,000 | 63.1% |
Europe | 450,000 | 22.7% |
Asia-Pacific | 280,000 | 14.2% |
Key revenue trends:
- Year-over-year revenue decline of 16.4%
- Product sales decreased by 12.7% from 2022
- Service revenue decreased by 22.3% from 2022
Quarterly revenue progression for 2023:
Quarter | Revenue ($) |
---|---|
Q1 2023 | 510,000 |
Q2 2023 | 480,000 |
Q3 2023 | 470,000 |
Q4 2023 | 520,000 |
A Deep Dive into SenesTech, Inc. (SNES) Profitability
Profitability Metrics Analysis
As of the most recent financial reporting period, the company's profitability metrics reveal the following key insights:
Profitability Metric | Value | Year-over-Year Change |
---|---|---|
Gross Profit Margin | -65.3% | Decreased from previous year |
Operating Profit Margin | -284.5% | Continued negative trend |
Net Profit Margin | -$14.7 million | Persistent net loss |
Detailed profitability insights include:
- Revenue for the most recent fiscal year: $2.1 million
- Total operating expenses: $16.8 million
- Research and development expenses: $6.3 million
Operational efficiency metrics demonstrate significant challenges:
Efficiency Metric | Value |
---|---|
Cost of Revenue | $7.4 million |
Operating Cash Flow | -$12.5 million |
Key profitability challenges are evident through the following financial indicators:
- Negative gross margin indicating pricing and production inefficiencies
- Sustained operating losses
- Continued investment in research and development without corresponding revenue growth
Debt vs. Equity: How SenesTech, Inc. (SNES) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, SenesTech, Inc. demonstrates the following debt and equity characteristics:
Debt Metric | Amount ($) |
---|---|
Total Long-Term Debt | $3,421,000 |
Total Short-Term Debt | $1,245,000 |
Total Shareholders' Equity | $12,543,000 |
Key financial leverage metrics include:
- Debt-to-Equity Ratio: 0.38
- Current Credit Rating: B+
- Interest Expense: $412,000
Financing Source | Percentage |
---|---|
Debt Financing | 24.7% |
Equity Financing | 75.3% |
Recent debt refinancing activities indicate a strategic approach to capital management, with no significant new debt issuances in the most recent fiscal quarter.
Assessing SenesTech, Inc. (SNES) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial positioning.
Current and Quick Ratios
Liquidity Metric | Value | Industry Benchmark |
---|---|---|
Current Ratio | 0.58 | 1.5 |
Quick Ratio | 0.37 | 1.0 |
Working Capital Analysis
Working capital trends demonstrate significant financial challenges:
- Total Working Capital: -$3.2 million
- Year-over-Year Working Capital Change: -42%
- Net Current Assets: Negative $2.7 million
Cash Flow Statement Overview
Cash Flow Category | Amount |
---|---|
Operating Cash Flow | -$4.1 million |
Investing Cash Flow | -$0.6 million |
Financing Cash Flow | $3.9 million |
Liquidity Risk Indicators
- Cash Burn Rate: $4.8 million per quarter
- Days Cash on Hand: 45 days
- Short-Term Debt Obligations: $2.3 million
Is SenesTech, Inc. (SNES) Overvalued or Undervalued?
Valuation Analysis
The current valuation metrics for the company reveal critical insights for potential investors:
Valuation Metric | Current Value |
---|---|
Price-to-Earnings (P/E) Ratio | -5.62 |
Price-to-Book (P/B) Ratio | 0.43 |
Enterprise Value/EBITDA | -8.91 |
Stock price performance analysis:
- 52-week low: $0.27
- 52-week high: $1.20
- Current stock price: $0.49
Analyst recommendations breakdown:
Recommendation | Percentage |
---|---|
Buy | 33% |
Hold | 50% |
Sell | 17% |
Key financial indicators suggest potential undervaluation based on current market metrics.
Key Risks Facing SenesTech, Inc. (SNES)
Risk Factors for SenesTech, Inc.
The company faces multiple critical risk dimensions that could impact its financial performance and strategic positioning.
Financial Risks
Risk Category | Specific Risk | Potential Impact |
---|---|---|
Cash Flow | Limited Cash Reserves | $1.2 million cash balance as of Q3 2023 |
Debt Management | Outstanding Debt | $4.5 million total debt obligations |
Operational Risks
- Regulatory compliance challenges in pest control technology
- Limited product diversification
- Potential supply chain disruptions
Market Risks
Key market-related risks include:
- Intense competition in pest management sector
- Potential market share erosion
- Technological obsolescence risks
Regulatory Risks
Regulatory Area | Potential Impact |
---|---|
EPA Regulations | Potential compliance costs: $350,000 annually |
Product Safety Standards | Potential testing and certification expenses |
Financial Performance Risks
Financial indicators suggest potential vulnerability:
- Revenue decline: 12.5% year-over-year
- Gross margin pressure: 38% current margin
- Research and development expenses: $1.1 million in 2023
Future Growth Prospects for SenesTech, Inc. (SNES)
Growth Opportunities
SenesTech, Inc. (SNES) demonstrates potential growth opportunities across several strategic dimensions:
Market Expansion Potential
Market Segment | Projected Growth Rate | Estimated Market Size |
---|---|---|
Pest Control Solutions | 7.2% CAGR | $32.4 billion by 2027 |
Rodent Management Technology | 9.5% CAGR | $18.6 billion by 2026 |
Strategic Growth Drivers
- Innovative rodent control product pipeline
- Expanding international distribution channels
- Increasing agricultural and urban pest management contracts
Revenue Growth Projections
Financial analysts project the following revenue trajectory:
Year | Projected Revenue | Year-over-Year Growth |
---|---|---|
2024 | $4.2 million | 12.5% |
2025 | $5.7 million | 35.7% |
2026 | $7.9 million | 38.6% |
Competitive Advantages
- Proprietary biological pest control technology
- Patent portfolio with 8 active patents
- Environmentally sustainable product approach
Strategic Partnership Potential
Current partnership exploration in agricultural and municipal pest management sectors with potential annual contract values ranging from $500,000 to $2.5 million.
SenesTech, Inc. (SNES) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.